Whiplash Associated Disorders

References

• Percy J. Whiplash syndrome: A doctor's dilemma. Can J CME 1994 July:63–7.
   Google Scholar
• Sutherland R. A crash course in whiplash management. Patient Care 1993; 9(10):25–34.
   Google Scholar
• Lord S, Barnsley L, Bogduk N. Cervical zygapophyseal joint pain in whiplash. Spine 1993;7(3):355–71.
   Google Scholar
• The Quebec Whiplash-Associated Disorders Cohort Study. Spine 1995;8S(20) Suppl. B:12–39.
   Google Scholar
• Nederhand MJ, IJzerman MJ, Hermens HJ, Baten CT, Zilvold G. Cervical muscle dysfunction in the chronic whiplash associated disorder grade II (WAD-II). Spine 2000;25(15):1938–43.
   Google Scholar
• Travell JG, Rinzler S, Herman M. Pain and disability of the shoulder and arm. Treatment by intramuscular infiltration with procaine hydrochloride. JAMA 1942;120:417–22.
   Google Scholar
• Fricton J. Myofascial pain and whiplash. Spine 1993;7(3):403–21.
   Google Scholar
• Speed CA. Injection therapies for soft-tissue disorders. Best Pract Res Clin Rheumatol. 2003 Feb;17(1):167–81.
   Google Scholar
• Drachman AB. Atrophy of skeletal muscle in chick embryos treated with botuli-num toxin. Science 1964;14(5)719–21.
   Google Scholar
• Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155–88.
   PubMed Web of Science ®Google Scholar
• Melling J, Hambleton P, Shone CC. Clostridium botulinum toxins: Nature and preparation for clinical use. Eye 1988;216–23.
   Google Scholar
• Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngologica 1993 May;113(3):400–4.
   PubMed Web of Science ®Google Scholar
• Holds JB, Alderson K, Fogg SG. Anderson, RL. Motor nerve sprouting in human orbicularis muscle following botulinum toxin A injection. Invest. Ophthalmol Vis Res. 1990;31:964–7.
   PubMed Web of Science ®Google Scholar
• Borodic, GE, Acquadro, M, Johnson, EA. Botulinum toxin therapy for pain and inflammatory disorders: Mechanisms and therapeutic effects. Expert Opin Invest. Drugs 2001;10(8):1531–44.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Bakheit A, McLellan D. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disability & Rehab: An Int Multidisciplinary J. 1998 Feb;20(2):62–5.
   PubMed Web of Science ®Google Scholar
• Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. Journal of Pain April 2003; 4(3):159–65.
   Google Scholar
• Cui M, Aoki R. Botulinum toxin type-A reduces inflammatory pain in the rat formalin model. Cephalalgia 2000;20(4):41.
   Google Scholar
• Merayo-Lloves J, Calonge M, Foster C. Experimental model of allergic conjunctivitis to ragweed in guinea-pig. Curr Eye Research 1995;14(6):487–94.
   PubMed Web of Science ®Google Scholar
• Dubner R, Sessle BJ, Storey AT. The Neural Basis of Oral and Facial Function, Plenum, New York, pp 483, 1978.
   Google Scholar
• Saldanha G, Hongo J, Plant G, Acheson J, Levy I, Anand P. Decreased CGRP, but preserved Trk A immunoreactivity in nerve fibres in inflamed human superficial temporal arteries. Journal of Neurology, Neurosurgery & Psychiatry 1999; 66(3): 390–92.
   Google Scholar
• Jung HH, Lauterburg T, Burgunder JM. Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997 May;78(2):469–79.
   Google Scholar
• Meunier FA, Colasante C, Faille L, Gastard M, Molgo J. Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botuli-num type-A toxin. Pflugers Arch. 1996;431(6 Suppl 2): R297–8.
   Google Scholar
• Tarabal O, Caldero J, Ribera J, Sorribas A, Lopez R, Molgo J, Esquerda JE. Regulation of motoneuronal calcitonin gene-related peptide (CGRP) during axonal growth and neuromuscular synaptic plasticity induced by botulinum toxin in rats. Eur J Neurosci. 1996 Apr;8(4):829–36.
   Google Scholar
• Freund B, Schwartz M. Treatment of whiplash associated neck pain with botuli-num toxin-A: A pilot study. Journal of Rheumatology 2000;27(3):481–4.
   Google Scholar
• Freund B, Schwartz M. Treatment of cervical-associated headache with botulinum toxin-A: A pilot study. Headache 2000;40(3):231–6.
   PubMed Web of Science ®Google Scholar
• Freund B, Schwartz M. A new treatment for temporomandibular disorders using botulinum toxin. British Journal of Oral Surgery 2000; 38(5):466–71.
   Google Scholar
• Hu, JW. Cephalic myofascial pain pathways, in Tension-type Headache: Classification, Mechanisms and Treatment, J Olesen, J Schoenen, Eds. Raven Press Ltd., New York, 69-77, 1993.
   Google Scholar
• Mense S. Considerations concerning the neurobiological basis of muscle pain. Can J Physiol Pharmacol. 1991;69:610–16.
   PubMed Web of Science ®Google Scholar
• Mense S, Meyer H. Bradykinin induced modulation of the response behavior of different types of feline group III andIV muscle receptors. J Physiol. 1988; 398:49–63.
   PubMedGoogle Scholar
• Morley JE, Kay NE, Solomon GF, Plotnikoff NP. Neuropeptides: Conductors of the immune orchestra. Life Sci. 1987;41:527–44.
   PubMed Web of Science ®Google Scholar
• Taiwo YO, Bjerknes LK, Goetzl EJ, Levine JD. Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 1990; 32:577–80.
   Google Scholar
• Lotz M, Carson DA, Vaughn JH. Substance P activation of rheumatoid synoviocytes: Neural pathway in pathogenesis of arthritis. Science 1987;235:893–5.
   PubMed Web of Science ®Google Scholar
• Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenalin hyperalgesia is mediated through interaction with sympathetic postganglionic neuron terminals rather than activation of primary afferent nociceptors. Nature 1986;323:158–60.
   PubMed Web of Science ®Google Scholar
• Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 1993;54(3):241–89.
   PubMed Web of Science ®Google Scholar
• Sessle BJ. Biological & Psychological Aspects of Orofacial Pain. CS Stohler, DS Carlson, Eds., Craniofacial Growth Series 29, Center for Human Growth & Development, The University of Michigan, Ann Arbor, 1994.
   Google Scholar
• Hylden JLK, Nahin RL, Traub RJ, Dubner R. Expansion if receptive fields of spinal lamina 1 projection neurons in rats with unilateral adjuvant induced inflammation: The contribution of dorsal horn mechanisms. Pain 1989;37:229–43.
   PubMed Web of Science ®Google Scholar
• Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther. 2003 Mar;25(3):852–89.
   Google Scholar
• Sist TC, Filadora VA 2nd, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and neck: Report of ten cases. Reg Anesth. 1997 Sep-Oct;22(5):473–8.
   Google Scholar
• Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 2003 Jan-Feb;19(1):59–68.
   Google Scholar
• Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003 Sep; 105 (1-2): 133–41.
   PubMedGoogle Scholar